Back

Machine learning approaches based on fibroblast morphometry confidently identify stress but have limited ability to predict ALS

Konrad, C.; Woo, E.; Bredvik, K.; Liu, B.; Fuchs, T. J.; Manfredi, G.

2022-10-24 neuroscience
10.1101/2022.10.23.513410 bioRxiv
Show abstract

ObjectiveAmyotrophic lateral sclerosis (ALS) is a devastating neuromuscular disease with limited therapeutic options. Diagnostic and surrogate endpoint biomarkers are needed for early disease detection, clinical trial design, and personalized medicine. MethodsWe tested the predictive power of a large set of primary skin fibroblast (n=443) from sporadic and familial ALS patients and healthy controls. We measured morphometric features of endoplasmic reticulum, mitochondria, and lysosomes by imaging with vital dyes. We also analysed immunofluorescence images of ALS-linked proteins, including TDP-43 and stress granule components. We studied fibroblasts under basal conditions and under metabolic (galactose medium), oxidative (arsenite), and heat stress conditions. We then employed machine learning (ML) techniques on the dataset to develop biomarkers. ResultsStress perturbations caused robust changes in the measured features, such as organellar morphology, stress granule formation, and TDP-43 mislocalization. ML approaches were able to predict the perturbation with near perfect performance (ROC-AUC > 0.99). However, when trying to predict disease state or disease groups (e.g., sporadic, or familial ALS), the performance of the ML algorithm was more modest (ROC-AUC Control vs ALS = 0.63). We also detected modest but significant scores when predicting clinical features, such as age of onset (ROC-AUC late vs early = 0.60). ConclusionsOur findings indicate that the ML morphometry we developed can accurately predict if human fibroblasts are under stress, but the differences between ALS and controls, while statistically significant, are small and pose a challenge for the development of biomarkers for clinical use by these approaches.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Neuropathology and Applied Neurobiology
14 papers in training set
Top 0.1%
13.2%
2
Scientific Reports
3102 papers in training set
Top 7%
9.5%
3
Neurobiology of Disease
134 papers in training set
Top 0.8%
6.6%
4
PLOS ONE
4510 papers in training set
Top 30%
5.0%
5
Brain Communications
147 papers in training set
Top 0.3%
5.0%
6
Annals of Clinical and Translational Neurology
29 papers in training set
Top 0.1%
5.0%
7
Frontiers in Cellular Neuroscience
79 papers in training set
Top 0.1%
4.1%
8
Annals of Neurology
57 papers in training set
Top 0.4%
4.1%
50% of probability mass above
9
Frontiers in Neurology
91 papers in training set
Top 1%
4.0%
10
Journal of Neurology
26 papers in training set
Top 0.3%
2.7%
11
Experimental Neurology
57 papers in training set
Top 0.5%
1.9%
12
Muscle & Nerve
10 papers in training set
Top 0.2%
1.8%
13
Frontiers in Psychiatry
83 papers in training set
Top 2%
1.7%
14
eneuro
389 papers in training set
Top 6%
1.4%
15
eBioMedicine
130 papers in training set
Top 2%
1.3%
16
Wellcome Open Research
57 papers in training set
Top 1%
1.2%
17
Frontiers in Aging Neuroscience
67 papers in training set
Top 3%
1.0%
18
Nature Communications
4913 papers in training set
Top 60%
0.8%
19
GeroScience
97 papers in training set
Top 1%
0.8%
20
Disease Models & Mechanisms
119 papers in training set
Top 2%
0.8%
21
Neurology
44 papers in training set
Top 1%
0.8%
22
Brain
154 papers in training set
Top 4%
0.8%
23
Human Molecular Genetics
130 papers in training set
Top 3%
0.8%
24
Frontiers in Human Neuroscience
67 papers in training set
Top 2%
0.8%
25
Neurorehabilitation and Neural Repair
17 papers in training set
Top 0.5%
0.7%
26
NeuroImage: Clinical
132 papers in training set
Top 4%
0.7%
27
npj Parkinson's Disease
89 papers in training set
Top 1%
0.7%
28
Journal of Parkinson's Disease
13 papers in training set
Top 0.4%
0.7%
29
Neurology Genetics
14 papers in training set
Top 0.4%
0.7%
30
Alzheimer's & Dementia
143 papers in training set
Top 3%
0.7%